Abstract
Green tea is now known to be the most effective beverage for cancer prevention, and evidence of this was recently extended to clinical applications. This paper briefly reviews several topics with regard to the development of our study on cancer prevention with green tea, and proposes a strategy for two-stages of cancer prevention with green tea. The topics are : 1) introduction of our initial work on (-)-epigallocatechin gallate (EGCG), the main constituent of Japanese green tea; 2) cancer preventive effects of EGCG and green tea extract, the lyophilized form of green tea infusion; 3) bioavailability of 3H-EGCG in mice; 4) delay of cancer onset by drinking 10 Japanese-size cups of green tea per day; 5) a prototype study for developing green tea beverage supplemented with green tea tablets by 102 healthy volunteers; 6) cancer prevention before cancer onset for the general population and high risk groups; 7) cancer prevention for patients following cancer treatment; 8) an example of a clinical trial looking toward prevention of cancer recurrence in the liver; and 9) possible prevention of human lung cancer. Considering all the above, green tea is a multi-, non-toxic cancer preventive for humans: It is natures remedy.
Keywords: green tea, egcg, 10 japanese-size cups, general population, cancer patients
Current Cancer Therapy Reviews
Title: Cancer Prevention with Green Tea Polyphenols for the General Population, and for Patients Following Cancer Treatment
Volume: 1 Issue: 1
Author(s): Hirota Fujiki, Masami Suganuma, Satoru Matsuyama and Kohji Miyazaki
Affiliation:
Keywords: green tea, egcg, 10 japanese-size cups, general population, cancer patients
Abstract: Green tea is now known to be the most effective beverage for cancer prevention, and evidence of this was recently extended to clinical applications. This paper briefly reviews several topics with regard to the development of our study on cancer prevention with green tea, and proposes a strategy for two-stages of cancer prevention with green tea. The topics are : 1) introduction of our initial work on (-)-epigallocatechin gallate (EGCG), the main constituent of Japanese green tea; 2) cancer preventive effects of EGCG and green tea extract, the lyophilized form of green tea infusion; 3) bioavailability of 3H-EGCG in mice; 4) delay of cancer onset by drinking 10 Japanese-size cups of green tea per day; 5) a prototype study for developing green tea beverage supplemented with green tea tablets by 102 healthy volunteers; 6) cancer prevention before cancer onset for the general population and high risk groups; 7) cancer prevention for patients following cancer treatment; 8) an example of a clinical trial looking toward prevention of cancer recurrence in the liver; and 9) possible prevention of human lung cancer. Considering all the above, green tea is a multi-, non-toxic cancer preventive for humans: It is natures remedy.
Export Options
About this article
Cite this article as:
Fujiki Hirota, Suganuma Masami, Matsuyama Satoru and Miyazaki Kohji, Cancer Prevention with Green Tea Polyphenols for the General Population, and for Patients Following Cancer Treatment, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952474
DOI https://dx.doi.org/10.2174/1573394052952474 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Carbon Nanotubes: An Emerging Drug Delivery Carrier in Cancer Therapeutics
Current Drug Delivery Development and Assessment of Conventional and Targeted Drug Combinations for Use in the Treatment of Aggressive Breast Cancers
Current Cancer Drug Targets Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design Obesity in the Patient with Lung Disease
Current Respiratory Medicine Reviews Glyoxalase 1 and 2 Enzyme Inhibitory Activity of 6-Sulfamoylsaccharin and Sulfocoumarin Derivates
Letters in Drug Design & Discovery Development of Cancer Vaccine Targeting WT1 Product which is Expressed in Various Kinds of Malignant Neoplasms
Medicinal Chemistry Reviews - Online (Discontinued) Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Proteomic and Glycomic Markers to Differentiate Lung Adenocarcinoma from COPD
Current Medicinal Chemistry LncRNA in Tumorigenesis Microenvironment
Current Bioinformatics CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism BCL-2 Family Proteins: The Mitochondrial Apoptotic Key Regulators
Current Cancer Therapy Reviews Breaking the Barrier of Cancer Through Liposome Loaded with Phytochemicals
Current Drug Delivery The Rationale of Targeting Neutrophils with Dapsone during Glioblastoma Treatment
Anti-Cancer Agents in Medicinal Chemistry Anaesthesia in Cancer Surgery: Can it Affect Cancer Survival?
Current Clinical Pharmacology Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Targeting the Hippo Pathway for Anti-cancer Therapies
Current Medicinal Chemistry Estrogen(s) and Analogs as a Non-Immunogenic Endogenous Ligand in Targeted Drug/DNA Delivery
Current Medicinal Chemistry Nuclear Imaging of Prostate Cancer with Gastrin-Releasing-Peptide- Receptor Targeted Radiopharmaceuticals
Current Pharmaceutical Design Mass Spectrometric Strategies and Their Applications for Molecular Mass Determination of Recombinant Therapeutic Proteins
Current Pharmaceutical Biotechnology Angiotensin-Converting Enzyme 2 Roles in the Pathogenesis of COVID-19
Current Hypertension Reviews